AR083588A1 - Forma cristalina de 13-[(n-tert-butoxicarbonil)-2’-o-hexanoil-3-fenilsoserinil]-10-deacetilbaccatina iii y proceso para prepararla - Google Patents
Forma cristalina de 13-[(n-tert-butoxicarbonil)-2’-o-hexanoil-3-fenilsoserinil]-10-deacetilbaccatina iii y proceso para prepararlaInfo
- Publication number
- AR083588A1 AR083588A1 ARP110103990A ARP110103990A AR083588A1 AR 083588 A1 AR083588 A1 AR 083588A1 AR P110103990 A ARP110103990 A AR P110103990A AR P110103990 A ARP110103990 A AR P110103990A AR 083588 A1 AR083588 A1 AR 083588A1
- Authority
- AR
- Argentina
- Prior art keywords
- tert
- phenylososinin
- hexanoil
- deacetilbaccatine
- butoxicarbonil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
13-[(N-tert-butoxicarbonil)-2’-O-hexanoil-3-fenilisoserinil]-10-deacetilbaccatina III en una forma cristalina; es decir la forma cristalina A.Reivindicación 3: La forma cristalina de 13-[(N-tert-butoxicarbonil)-2’-O-hexanoil-3-fenilisoserinil]-10-deacetilbaccatina III de acuerdo con la reivindicación 2, caracterizada porque la Forma cristalina A tiene un difractograma de XRPD que se caracteriza por los siguientes picos: 6,1; 9,1; 10,1; 10,6; 11,7; 13,0; 18,5; 19,8; 22,0 grados 2-q ± 0,2º.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10189373A EP2447268A1 (en) | 2010-10-29 | 2010-10-29 | Crystalline form of 13-[(N-tert-butoxycarbonyl)-2'-O-hexanoyl-3-phenylisoserinyl]-10-deacetylbaccatin III |
Publications (1)
Publication Number | Publication Date |
---|---|
AR083588A1 true AR083588A1 (es) | 2013-03-06 |
Family
ID=43886731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110103990A AR083588A1 (es) | 2010-10-29 | 2011-10-28 | Forma cristalina de 13-[(n-tert-butoxicarbonil)-2’-o-hexanoil-3-fenilsoserinil]-10-deacetilbaccatina iii y proceso para prepararla |
Country Status (16)
Country | Link |
---|---|
US (1) | US9062018B2 (es) |
EP (2) | EP2447268A1 (es) |
JP (1) | JP5744215B2 (es) |
KR (2) | KR101577177B1 (es) |
CN (1) | CN103209983B (es) |
AR (1) | AR083588A1 (es) |
AU (1) | AU2011322572B2 (es) |
CA (1) | CA2814907C (es) |
DK (1) | DK2632926T3 (es) |
ES (1) | ES2528374T3 (es) |
MX (1) | MX2013004722A (es) |
PL (1) | PL2632926T3 (es) |
PT (1) | PT2632926E (es) |
RU (1) | RU2546661C2 (es) |
SI (1) | SI2632926T1 (es) |
WO (1) | WO2012055952A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1457492B1 (en) | 2001-11-29 | 2008-01-02 | Daiichi Sankyo Company, Limited | Crystals of taxane derivative and process for their production |
ES2663495T3 (es) * | 2005-02-18 | 2018-04-13 | Abraxis Bioscience, Llc | Fármacos con hidrofobicidad mejorada para incorporación en dispositivos médicos |
NZ576355A (en) | 2006-10-20 | 2012-04-27 | Scinopharm Singapore Pte Ltd | Process for making crystalline anhydrous docetaxel |
KR20150136137A (ko) | 2008-04-10 | 2015-12-04 | 아브락시스 바이오사이언스, 엘엘씨 | 소수성 탁산 유도체의 조성물 및 그의 용도 |
-
2010
- 2010-10-29 EP EP10189373A patent/EP2447268A1/en not_active Withdrawn
-
2011
- 2011-10-27 EP EP11776758.2A patent/EP2632926B1/en not_active Not-in-force
- 2011-10-27 RU RU2013124011/04A patent/RU2546661C2/ru not_active IP Right Cessation
- 2011-10-27 KR KR1020157021873A patent/KR101577177B1/ko active IP Right Grant
- 2011-10-27 MX MX2013004722A patent/MX2013004722A/es active IP Right Grant
- 2011-10-27 AU AU2011322572A patent/AU2011322572B2/en not_active Ceased
- 2011-10-27 ES ES11776758.2T patent/ES2528374T3/es active Active
- 2011-10-27 KR KR1020137013510A patent/KR20130086618A/ko not_active Application Discontinuation
- 2011-10-27 PL PL11776758T patent/PL2632926T3/pl unknown
- 2011-10-27 CA CA2814907A patent/CA2814907C/en not_active Expired - Fee Related
- 2011-10-27 US US13/882,014 patent/US9062018B2/en not_active Expired - Fee Related
- 2011-10-27 CN CN201180052582.2A patent/CN103209983B/zh not_active Expired - Fee Related
- 2011-10-27 DK DK11776758.2T patent/DK2632926T3/en active
- 2011-10-27 JP JP2013535432A patent/JP5744215B2/ja not_active Expired - Fee Related
- 2011-10-27 WO PCT/EP2011/068835 patent/WO2012055952A1/en active Application Filing
- 2011-10-27 PT PT117767582T patent/PT2632926E/pt unknown
- 2011-10-27 SI SI201130381T patent/SI2632926T1/sl unknown
- 2011-10-28 AR ARP110103990A patent/AR083588A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US9062018B2 (en) | 2015-06-23 |
KR20130086618A (ko) | 2013-08-02 |
CA2814907A1 (en) | 2012-05-03 |
RU2013124011A (ru) | 2014-12-10 |
AU2011322572B2 (en) | 2015-02-19 |
AU2011322572A1 (en) | 2013-05-02 |
KR20150099614A (ko) | 2015-08-31 |
PT2632926E (pt) | 2015-02-09 |
CN103209983A (zh) | 2013-07-17 |
ES2528374T3 (es) | 2015-02-09 |
WO2012055952A1 (en) | 2012-05-03 |
EP2632926A1 (en) | 2013-09-04 |
MX2013004722A (es) | 2013-08-29 |
DK2632926T3 (en) | 2015-01-12 |
CA2814907C (en) | 2015-02-03 |
PL2632926T3 (pl) | 2015-04-30 |
JP2013540798A (ja) | 2013-11-07 |
KR101577177B1 (ko) | 2015-12-14 |
US20140303240A1 (en) | 2014-10-09 |
SI2632926T1 (sl) | 2015-03-31 |
CN103209983B (zh) | 2016-04-13 |
JP5744215B2 (ja) | 2015-07-08 |
EP2632926B1 (en) | 2014-12-10 |
EP2447268A1 (en) | 2012-05-02 |
RU2546661C2 (ru) | 2015-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6480954A2 (es) | Método para producir una preparación altamente concentrada de inmunoglobulina de uso subcutaneo | |
MX2010002836A (es) | Bortezomib y proceso para la produccion del mismo. | |
AR063347A1 (es) | Formas cristalinas de docetaxel y proceso para su preparacion | |
BR112015005404A2 (pt) | Formas polimórficas de enzalutamida e sua preparação | |
BR112013022625A2 (pt) | quadros policristalinos, elementos policristalinos, e métodos relacionados | |
BR112012000304A8 (pt) | processo para a desidratação de etanol para produzir eteno | |
BR112014008214A2 (pt) | composto, processo de síntese de peptídeo em fase sólida para preparar um composto, processo, composição e uso do composto | |
BRPI1010128A2 (pt) | "processo para a fabricação do 2,3,3,3 - tetrafluropropeno" | |
CA2818957A1 (fr) | Procede d'elimination de derives a base de siloxane d'une phase organique liquide | |
CL2014000441A1 (es) | Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer. | |
IN2012DN01968A (es) | ||
WO2012042534A3 (en) | Preparation of r-sitagliptin and intermediates thereof | |
ECSP10010499A (es) | Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida | |
MX2015010165A (es) | Metodo para reducir el consumo de energia mediante acoplamiento termico. | |
CL2008001513A1 (es) | Uso de hidrofobinas como auxiliares en la cristalizacion de un solido; proceso para la produccion de un solido por cristalizacion a partir de una fase acuosa y separando el solido formado desder la fase acuosa. | |
CL2012003371A1 (es) | Compuestos intermediarios de la síntesis de agomelatina; y el procedimiento de obtención de agomelatina a partir de dichos compuestos intermediarios | |
MX337997B (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
BR112012026411A2 (pt) | processo para preparar ditiina-tetracarboxi-diiminas | |
CL2012001081A1 (es) | Procesos de preparcion de compuestos intermediarios en la sintesis de valsartan por hidrolisis de un ester utilizando salesde aluminio. | |
BR112012022928A2 (pt) | beta-hidroxialquilamidas, processo para sua produção, bem como seu uso | |
AR083588A1 (es) | Forma cristalina de 13-[(n-tert-butoxicarbonil)-2’-o-hexanoil-3-fenilsoserinil]-10-deacetilbaccatina iii y proceso para prepararla | |
EA201200150A1 (ru) | Новые гербициды | |
BRPI0907545A2 (pt) | Processo para a preparação contínua de 1, 3-dioxolan-2-ona | |
BR112013009176A2 (pt) | processo para a síntese de álcoois quirais propargílicos. | |
EA201490536A1 (ru) | Новая кристаллическая форма |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |